These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Mechanistic study of the transmission pattern of the SARS-CoV-2 omicron variant. An K; Yang X; Luo M; Yan J; Xu P; Zhang H; Li Y; Wu S; Warshel A; Bai C Proteins; 2024 Jun; 92(6):705-719. PubMed ID: 38183172 [TBL] [Abstract][Full Text] [Related]
44. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. Bayarri-Olmos R; Rosbjerg A; Johnsen LB; Helgstrand C; Bak-Thomsen T; Garred P; Skjoedt MO J Biol Chem; 2021; 296():100536. PubMed ID: 33716040 [TBL] [Abstract][Full Text] [Related]
45. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
46. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
47. Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. Verkhivker GM J Proteome Res; 2020 Nov; 19(11):4587-4608. PubMed ID: 33006900 [TBL] [Abstract][Full Text] [Related]
48. Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function. Yang TJ; Yu PY; Chang YC; Liang KH; Tso HC; Ho MR; Chen WY; Lin HT; Wu HC; Hsu SD Nat Struct Mol Biol; 2021 Sep; 28(9):731-739. PubMed ID: 34385690 [TBL] [Abstract][Full Text] [Related]
49. Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein. Bhattacharjee S; Bhattacharyya R; Sengupta J FEBS Lett; 2021 Feb; 595(4):442-451. PubMed ID: 33449359 [TBL] [Abstract][Full Text] [Related]
50. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260 [TBL] [Abstract][Full Text] [Related]
51. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663 [TBL] [Abstract][Full Text] [Related]
52. Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor. Spinello A; Saltalamacchia A; BoriĊĦek J; Magistrato A J Phys Chem Lett; 2021 Jul; 12(25):5987-5993. PubMed ID: 34161095 [TBL] [Abstract][Full Text] [Related]
53. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. Chakraborty S Biochem Biophys Res Commun; 2021 Jan; 534():374-380. PubMed ID: 33272568 [TBL] [Abstract][Full Text] [Related]
54. Structural basis of severe acute respiratory syndrome coronavirus 2 infection. Ge J; Zhang S; Zhang L; Wang X Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231 [TBL] [Abstract][Full Text] [Related]
55. Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor. Sitthiyotha T; Chunsrivirot S Sci Rep; 2021 Aug; 11(1):15650. PubMed ID: 34341401 [TBL] [Abstract][Full Text] [Related]
56. Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. Taft JM; Weber CR; Gao B; Ehling RA; Han J; Frei L; Metcalfe SW; Overath MD; Yermanos A; Kelton W; Reddy ST Cell; 2022 Oct; 185(21):4008-4022.e14. PubMed ID: 36150393 [TBL] [Abstract][Full Text] [Related]
57. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756 [TBL] [Abstract][Full Text] [Related]
58. Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. Alaofi AL; Shahid M Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572486 [TBL] [Abstract][Full Text] [Related]
59. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435 [TBL] [Abstract][Full Text] [Related]
60. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]